Preferred Label : Runimotamab;
NCIt synonyms : BTRC-4017A; Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody 4017A; Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody RG 6194; Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A; Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A;
NCIt definition : An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent
bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic
activities. Upon administration, runimotamab possesses two antigen recognition sites,
one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types,
and one for the CD3 complex, a group of T-cell surface glycoproteins that interact
with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific
monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing
cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes
(CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells.
HER2 plays a key role in tumor cell proliferation and tumor vascularization.;
UNII : F8Z9VSZ0K1;
CAS number : 2361325-98-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2361325-98-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : BTRC 4017A; RG-6194; BTRC4017A; RG 6194;
NCI Metathesaurus CUI : CL935873;
Origin ID : C156705;
UMLS CUI : C5554552;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
